$130 Million To $1 Billion, APFC’s Unrealized Gain on Juno
Posted on 02/19/2015
In greater frequency, sovereign wealth funds are participating as cornerstone investors, not just in Asia, but in U.S. pharmaceutical companies. Sovereign wealth centers on the importance of high-quality deal flow, eagerly waiting for special opportunities from their vast lineup of asset managers. These special opportunities can lead to outsized investment returns for public institutional investors. […]
- Alaska Permanent Fund Corporation
- Alternatives
- Crestline Investors
- Hedge Funds
- Juno Therapeutics
- pharmaceuticals
- Seattle
